You can now subscibe to a newsletter that will keep you updated on our progress.

 

We have decided to launch this newsletter further to the many requests we regularly receive for information on our work on the development of the therapeutic vaccine for myasthenia gravis.  We also receive many enquiries about our research on the use of complementary peptide vaccine technique for other auto-immune deseases like MS, diabetes type I and lupus, to name a few.

 

All of the funds generated through subscriptions to this newsletter will be 100% directly invested in manufacturing the MG vaccine. We intend funds generated through this newsletter to speed up our work and help us to reach our goal of a phase 1A trial as soon as possible. In this way, you will not only be aware of the latest progress but you will also help us to help MG patients to tackle this disease once and for all.

 

A newsletter copy should be considered as a private copy and is protected by copyright.  This means that you can print a copy to read and share with your familly and friends but you cannot send copies by email and duplicate the content. We count on your cooperation on this and on the fact that you want to help us to get to Phase 1A trial as soon as possible.  Again all the revenue generated by this newsletter will directly and solely be invested in manufacturing the MG vaccine.  If you know someone who wants to read it, encourage this person to subscibe so that the vaccine will be on the market faster.  Every penny counts.  Ask family, friends and businesses you know to subscribe.  Ask them to buy multiple copies for other patients you know. Not only will you help us to reach our common goal faster but also you will show to our investors or future investors that there is a real demand for this therapeutic vaccine.  The more newletters we sell, the more money we can spend to bring the MG vaccine out of the lab and to the patients who need it.

 

Subsribe now!

 

Thank you for your support.

 

Dr Stephane Huberty

CuraVac

CEO